AA
CRBP icon

Ancora Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Ancora Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$600 Hold
64
– – ﹤0.01% 1890
2026
Q1 		$601 Hold
64
– – ﹤0.01% 2276
2025
Q4 		$521 Hold
64
– – ﹤0.01% 2301
2025
Q3 		$810 Buy
+64
New +$609 ﹤0.01% 1784

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Ancora Advisors's CRBP Position: Q2 2026 in Review

Ancora Advisors held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 64 shares worth $600. The position accounts for ﹤0.01% of the portfolio, ranked #1890.

Ancora Advisors first reported a position in CRBP in Q3 2025 and has held it in 4 quarters since. The position peaked at $810 in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Ancora Advisors held 64 shares of Corbus Pharmaceuticals worth $600 as of Q2 2026.
  • Ancora Advisors left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1890 holding.
  • Ancora Advisors first reported a position in Corbus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Ancora Advisors's Corbus Pharmaceuticals position peaked at $810 in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.